Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration

被引：2

作者：

Gelissen, Liza M. Y. ^{[1
]}

Loveless, Sam ^{[2
]}

Toorop, Alyssa A. ^{[1
]}

Howlett, Jayne ^{[3
]}

Loeff, Floris C. ^{[4
]}

Rispens, Theo ^{[4
,5
]}

Killestein, Joep ^{[1
]}

Tallantyre, Emma C. ^{[2
,3
]}

van Kampen, Zoe L. E. ^{[1
]}

机构：

[1] Vrije Univ Amsterdam, MS Ctr Amsterdam, Dept Neurol, Neurol Outpatient Clin,Amsterdam Neurosci,Amsterda, De Boelelaan 1118, NL-1081HV Amsterdam, Netherlands

[2] Cardiff Univ, Inst Psychol Med & Clin Neurosci, Cardiff, Wales

[3] Univ Hosp Wales, Dept Neurol, Cardiff, Wales

[4] Sanquin Diag Serv, Biol Lab, Amsterdam, Netherlands

[5] Sanquin Res & Landsteiner Lab Acad Med Ctr, Dept Immunopathol, Amsterdam, Netherlands

来源：

MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2024年 / 90卷

关键词：

Multiple sclerosis; Natalizumab; Subcutaneous; Intravenous; Extended interval dosing; Personalised treatment;

D O I：

10.1016/j.msard.2024.105796

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: Several studies reported lower drug concentrations with subcutaneous natalizumab compared to intravenous natalizumab. With the emergence of extended interval dosing, gaining more insight into lower concentrations after subcutaneous administration is essential. Methods: We compared serum trough concentrations between subcutaneous and intravenous administration within a matched cohort (n = 50). Results: Subcutaneous administration (n = 25) was associated with lower concentrations compared to intravenous administration (n = 25) (log-B=-0.28, p = 0.01). In an exploratory group of 11 patients receiving extended interval dosing of subcutaneous natalizumab, the median trough concentration was even lower. Conclusion: Subcutaneous natalizumab can lead to lower drug concentrations, potentially limiting extended interval dosing.

引用

收藏

页数：4

相关论文

共 11 条

[1] Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial [J].

Foley, John F. ;

Defer, Gilles ;

Ryerson, Lana Zhovtis ;

Cohen, Jeffrey A. ;

Arnold, Douglas L. ;

Butzkueven, Helmut ;

Cutter, Gary ;

Giovannoni, Gavin ;

Killestein, Joep ;

Wiendl, Heinz ;

Smirnakis, Karen ;

Xiao, Shan ;

Kong, George ;

Kuhelj, Robert ;

Campbell, Nolan .

LANCET NEUROLOGY, 2022, 21 (07) :608-619

[2] Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing [J].

Foley, John F. ;

Goelz, Susan ;

Hoyt, Tamara ;

Christensen, Angelene ;

Metzger, Ryan R. .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 31 :65-71

[3] Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study [J].

Mealli, Fabrizia ;

Mattei, Alessandra ;

Mariottini, Alice ;

Massacesi, Luca .

MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (08) :1077-1080

[4] A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis [J].

Plavina, Tatiana ;

Fox, Edward J. ;

Lucas, Nisha ;

Muralidharan, Kumar Kandadi ;

Mikol, Daniel .

JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (10) :1254-1262

[5] Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody [J].

Rispens, Theo ;

van Leeuwen, Astrid ;

Vennegoor, Anke ;

Killestein, Joep ;

Aalberse, Rob C. ;

Wolbink, Gerrit J. ;

Aarden, Lucien A. .

ANALYTICAL BIOCHEMISTRY, 2011, 411 (02) :271-276

[6] Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing [J].

Ryerson, Lana Zhovtis ;

Foley, John ;

Chang, Ih ;

Kister, Ilya ;

Cutter, Gary ;

Metzger, Ryan R. ;

Goldberg, Judith D. ;

Li, Xiaochun ;

Riddle, Evan ;

Smirnakis, Karen ;

Kasliwal, Rachna ;

Ren, Zheng ;

Hotermans, Christophe ;

Ho, Pei-Ran ;

Campbell, Nolan .

NEUROLOGY, 2019, 93 (15) :E1452-E1462

[7]

Toorop AA, 2024, J NEUROL NEUROSUR PS, V95, P392, DOI 10.1136/jnnp-2023-332119

[8] Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis [J].

Toorop, Alyssa A. ;

van Kempen, Zoe L. E. ;

Steenhuis, Maurice ;

Nielsen, Jessica ;

Sinnige, L. G. F. ;

van Dijk, Gert ;

Roosendaal, Christiaan M. ;

Arnoldus, Edo P. J. ;

Hoitsma, Elske ;

Lissenberg-Witte, Birgit, I ;

de Jong, Brigit A. ;

van Oosten, Bob W. ;

Strijbis, Eva M. M. ;

Uitdehaag, Bernard M. J. ;

Rispens, Theo ;

Killestein, Joep .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2023, 94 (06) :482-486

[9] A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis [J].

Trojano, Maria ;

Ramio-Torrenta, Lluis ;

Grimaldi, Luigi M. E. ;

Lubetzki, Catherine ;

Schippling, Sven ;

Evans, Karleyton C. ;

Ren, Zheng ;

Muralidharan, Kumar Kandadi ;

Licata, Stephanie ;

Gafson, Arie R. .

MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (14) :2240-2253

[10] The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing [J].

van Kempen, Zoe L. E. ;

Leurs, Cyra E. ;

Witte, Birgit I. ;

de Vries, Annick ;

Wattjes, Mike P. ;

Rispens, Theo ;

Killestein, Joep .

MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (06) :805-810